Business
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec.
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"--Non-Dilutive Grant Funding to Support Development of Brown Adipose-Based Therapeutic Programs Directed at Polycystic Ovary Syndrome -- MELVILLE, N.Y., Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health. This collaborative research will be conducted in partnership with Dr. Sheng Wu, Associate Professor, Center for Metabolic Disease Research at Temple University, School of Medicine, Dr. Wu has received numerous national and international awards such as the Women in Endocrinology Young Investigator Award, Eugenia Rosemberg Abstract Award, Early Investigator Award from the Endocrine Society; Virendra B. Mahesh Award of Excellence in Endocrinology, and Endocrinology and Metabolism Section New Investigator Award from American Physiology Society. The specific objective of this NIH grant is to enable the development and evaluation of the Company’s ThermoStem® program for the treatment of polycystic ovary syndrome (PCOS). Therapeutic brown adipocyte transplantation is an emerging and novel therapy for PCOS. BRTX has developed proprietary methods for the generation of metabolically active brown adipocytes. “This new indication will expand BioRestorative’s current discovery pipeline focused on the novel brown fat therapy at the intersection of innate, adaptive metabolic regulation and women’s health. Our industry expertise in brown fat complements world class research conducted by Dr. Wu’s laboratory and thus strengthen our commitment to discover innovative solutions for patients with unmet medical needs.” said Lance Alstodt, CEO of BioRestorative Therapies. PCOS affects 6-18% of reproductive age females, representing the most common endocrine disease in women and a $4.36 billion healthcare cost annually in the US. PCOS causes gynecological, dermatologic and metabolic comorbidities, and also imposes long-term risks of diabetes mellitus type 2 (T2D), cardiovascular diseases (CVD) and psychiatric problems including severe depression. PCOS is commonly associated with metabolic disorders, ...